Cargando…
Direct GDP-KRAS(G12C) inhibitors and mechanisms of resistance: the tip of the iceberg
Kirsten rat sarcoma viral oncogene homolog mutations are observed in 25% of lung adenocarcinoma and 40% of these are G12C mutations. Historically, no approved targeted agents were available for patients with any KRAS mutation, and response rates to standard-of-care therapies were suboptimal. Newly d...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026147/ https://www.ncbi.nlm.nih.gov/pubmed/36950276 http://dx.doi.org/10.1177/17588359231160141 |